Medesis Pharma is a clinical-stage Pharmaceutical Biotechnology company developing innovative technology (AONYS®) for the delivery of therapeutic molecules to treat diseases with no current efficacious treatment.
Medesis Pharma is listed on Euronext Growth Paris.
Legal structure :
- Montpellier (France) Headquarters
- Montreal (Canada) 100% subsidiary. Medesis Pharma Inc. is a subsidiary for collaborations with McGill University and the University of Montreal.
Medesis Pharma already has a long history.
Research program began in 1991 with the initiation of program investigating a plant extract for treatment of metabolic anomalies linked to insulin resistance.
After ten years of chemical purification (and more than 2,000 candidate molecules tested on animal models) the constituents of our micro-emulsion were identified, which evolved into a strictly pharmaceutical formulation: the water/oil micro-emulsion that we have called Aonys® .
Our technology and its multiple applications are protected by 11 international patents
Medesis Pharma was created in April 2003 and has, over the years, developed a substantial pipeline that now leads several future drugs into the clinic.
Our mission and our values
The primary mission of the company is medical — that is, the development of new drugs to treat diseases that are, to date, lacking effective treatments (e.g. neurodegenerative diseases, cancers and viral diseases, in particular COVID-19). We also have a financial objective, because only appropriate funding makes it possible to implement development plans and the validation of the efficacy and safety of each drug.
Since its creation, Medesis Pharma has been financed by private individuals who believed in our projects and their prospects (230 historical shareholders). In February 2021, the Company’s listing on Euronext Growth Paris created real momentum for our clinical development with patients.
To summarize the values of the company:
Always dreaming that we can achieve it.
Having the courage to move forward in a world of multiple constraints.
Combining rigor with enthusiasm!
Jean-Claude Maurel created Medesis Pharma in 2003. He trained as a medical doctor and has more than 30 years of experience in the research, development and marketing of drugs.
He created the Natura Medica laboratory in 1985, a pharmaceutical laboratory that developed and marketed extracts of medicinal plants, which was then sold in 1990 to IPSEN-BEAUFOUR.
In 1991, he created a research company that, after 10 years of chemical and pharmacological explorations, discovered the lipid constituents that today are the foundation of AONYS® technology.
In 2003, he created Medesis Pharma by bringing together patents and technical know-how.
Member of the Executive Board, Chief Medical Officer & Head of R&D
Solene Guilliot is a doctor of pharmacy with over 7 years of experience in medical affairs and clinical development. Previously, she held several international positions at Sanofi Genzyme and Bristol-Myers Squibb (United States, Canada, Germany and France). With her experience in neuroscience and immunology, in industry and in hospitals, she joined Medesis Pharma in 2021.
Member of the Executive Board, General Secretary
Mario Alcaraz holds a Master’s degree in Finance & Management, a Master’s degree in Management Control, a Diploma in Accounting and Management, as well as a Global Executive MBA. He is currently completing management courses at Berkeley University.
Mario is a former Chief Financial Officer and Head of Management Control. He served in various sectors of activity including that of Biotechnology where his functions also included investor relations and financial communication.
Chairman of the Board
Olivier Connes is Chairman of the Management Board of the Meridis Group, a supplier of industrial equipment specializing in planning, food processing and research. Partner at Solid Surfaces Applications, a company specializing in the wood and PVC joinery sector.
Robert J. Alonso
Walt A. Linscott
Robert J. Alonso
Walt A. Linscott
Scientific Advisory board
To carry out its projects, Medesis Pharma composed two advisory boards to benefit from guidance of field experts:
– Nanolithium in neurology – Advisory Board
Advisory board composed of neurologists, geriatricians, researchers who have had or have practical experience with lithium or Nanolithium in neurology. Their role is to review the data generated, ongoing studies, upcoming projects and guide the overall development of Medesis Pharma’s Nanolithium with a field perspective.
– Nanolithium in Alzheimer’s disease – Advisory Board
Advisory Board composed of international experts in Alzheimer’s disease to guide and advise Medesis Pharma in the development of Nanolithium in Alzheimer’s disease.
Dr. Edward N. Wilson
Researcher, PhD. San Francisco, USA
Dr. Guy Rouleau
Dr. Guy Rouleau is Director of The Neuro (Montreal Neurological Institute-Hospital), Chair of the Department of Neurology and Neurosurgery of McGill University, Director of the Department of Neuroscience of McGill University Health Centre, and co-founder of the Tanenbaum Open Science Institute.
He is also Vice-President of the World Federation of Neurology.
For more than 30 years, Dr. Guy Rouleau and his team have focused on identifying the genes causing several neurological and psychiatric diseases, including autism, amyotrophic lateral sclerosis, hereditary neuropathies, epilepsy and schizophrenia, as well as providing a better understanding of the molecular mechanisms that lead to these disease symptoms.
Among Dr. Rouleau’s main achievements are his contribution to the identification of dozens of disease-causing genes and his discovery of new mutational mechanisms.
Dr. Rouleau has published over 900 articles in peer-reviewed journals and has been quoted more than 95 000 times (Google Scholar).
He has supervised more than a hundred students at the Masters, PhD and Post-doctoral levels in addition to receiving numerous awards for his contribution to science and society.
Pr. Maria Soto Martin
Professor Maria Eugenia Soto Martin is geriatrician and head of the Alzheimer’s clinical and research center in the Department of Geriatric Medicine at the Toulouse University Hospital in France.
She is also head of the Aging and Disability Prevention Team of the Gerontopole, a WHO-collaborating center for Frailty, Clinical Research and Geriatric Training.
Currently, she leads with Professor Bruno Vellas the implementation of ICOPE WHO program in the region of Occitanie in France.
She is also a professor of Geriatric Medicine and she is member of the Research Aging Team MAINTAIN (CERPOP UMR 1295).
In 2009 she obtained a Master M2 degree in statistics and epidemiology from the Paul Sabatier University of Toulouse.
Pr. Soto has a PhD in Alzheimer’s disease and cognitive progression from the same University.
Currently she is principal investigator or coinvestigator of research programs focusing AD and neuropsychiatric symptoms. She has received grants from the French Ministry of Health Grant and the European Commission. She also participates as principal investigator or co-investigator in different pharmacological trials and collaborates with pharmaceutical industries to develop and enhance the therapeutic progress for neuropsychiatric symptoms in AD.
Since Mars 2022, Pr Soto is president of the French Federation of Memory Centers whose interest is to promote and evaluate the diagnostic, therapeutic and medico-social care of patients suffering from Alzheimer’s disease or related diseases whatever the stage of evolution, to participate in academic research and therapeutic trials to generate new advances in Alzheimer’s disease and related diseases, to mobilize for prevention in the field of cognition and aging and finally to engage in training and information concerning these diseases.
Pr. Jacques Touchon
Jacques Touchon is Emeritus Professor at Montpellier University France, member of the Institut des Neurosciences de Montpellier (INM) INSERM UNIT 1298. He is the Editor in Chief of the Journal of Prevention of Alzheimer’s disease (JPAD), co-Chairman and founding member of the of the Clinical Trials on Alzheimer’s Disease conference (CTAD).
Jacques Touchon obtained his medical degree in 1979, and from 1980 to 1984 degrees in neurology, psychiatry, neurophysiology and geriatric. Formerly, Jacques Touchon was Professor of Neurology at the Montpellier Medical School (1990-2014) Chief of the Neurology Department of the Montpellier University Hospital (2004-2014), Dean of the Montpellier Medical School (2000-2010), Director of the Center for Memory Resources and Research (CMRR) for the Languedoc-Roussillon region (2004-2014).
His areas of interest are Alzheimer’s Disease, aging and neurodegenerative diseases.
He was awarded for excellence in Alzheimer Disease Research: Academic Palms in 1999, PINEL prize in 2000 and in 2007 Chevalier de la Légion d’Honneur.
Dr. Mahmoud Pouladi
Dr. Mahmoud Pouladi is an Associate Professor of Medical Genetics at Columbia University in Canada.
He is a member of the BC Children’s Research Institute (BCCHRI), the Centre for Molecular Medicine and Therapeutics, and the Djavad Mowafaghian Centre for Brain Health in Vancouver.
Dr. Pouladi’s research focuses on the impact of genetic factors in the development of neurological disorders, for which he conducts extensive research using isogenic human pluripotent stem cells and transgenic animals to model disease, with the goal of defining new approaches for therapeutic intervention.
He focuses his research mainly on developmental and degenerative learning and memory disorders (Fragile X, Rett, Huntington’s disease), as well as white matter disorders (multiple sclerosis, hypomyelinating leukodystrophies).
Dr. Edward N. Wilson
Dr. Edward Wilson is a Professor of neurology at Stanford University in California, USA.
His research focuses primarily on Alzheimer’s disease, but also on Parkinson’s disease and other neurodegenerative diseases.
Dr. Wilson has extensive experience in pre-clinical research in these areas with numerous in vivo studies.
Dr. Cecilia Marelli
Dr Cecilia Marelli is a Neurologist at the Department of Neurology of the Gui de Chauliac Hospital in Montpellier.
Dr Marelli is involved in the genetic and metabolic components of neurodegenerative diseases, including Huntington’s disease, cerebellar ataxias and spastic paraplegia, and mitochondrial disorders.
She is head of the Montpellier Expert Center for Neurogenetic diseases and of the Montpellier Huntington’s Disease Expert Center.
Constantine George Lyketsos
He graduated from Athens College, then Northwestern University (B.A. in Psychology) and then received a Medical Doctorate at Washington University Medical School in St. Louis. He completed residency and Chief Residency in psychiatry at Johns Hopkins, as well as a fellowship in clinical epidemiology. A world-renowned expert in treatment development for Alzheimer’s disease and related disorders, he is an active clinician, teacher, and researcher.
Dr. Lyketsos founded the Johns Hopkins Memory and Alzheimer’s Treatment Center which he directs. He also founded and directs the Richman Family Precision Medicine Center of Excellence on Alzheimer’s Disease, and is Associate Director of NIH-funded Johns Hopkins Alzheimer’s Disease Research Center. Dr. Lyketsos has received multiple awards, and authored over 500 articles, as well as five books.
His work has been cited over 65,000 times with an h-index of 139. A 2021 Stanford University publication reported that he ranks #13 out of 9246 scientists worldwide (and all time) in the field of Geriatrics. Castle-Connolly has named him as one of America’s Top Doctors every year since 2001.
Previously Director of the Alzheimer Disease and Related Disorders Research Unit, McGill Center for Studies in Aging, Douglas Research Centre, Professor in Department of Neurology and Neurosurgery and Psychiatry in McGill University, Medical studies at Université de Montréal, Neurology training at McGill University, Research Fellowship at Prof. Theodore L. Sourkes laboratory, Allen Memorial Institute, Montreal. Clinical investigator and staff neurologist at the Montreal Neurological Hospital and Institute (1976-1986), Director of the McGill Centre for Studies in Aging (1886-1996), Senior Scientist of the CIHR-Rx&D program (1997-2007).
Currently Emeritus Professor in Neurology and in Psychiatry at McGill University. Contributions to research include design and implementation of randomized clinical trials in order to establish the safety and efficacy of cholinesterase inhibitors, muscarinic agonists, and agents possibly modifying progression for Alzheimer’s disease and vascular dementia. Special interests include consensus approach to the management of dementia in different stages, the ethics of research involving persons with dementia, and primary prevention strategies against cognitive decline and dementia.
Clinician Scientist and Professor of Psychiatry, Neurology, Epidemiology, and Pathology at the Hotchkiss Brain Institute and O’Brien Institute for Public Health, at the University of Calgary.
He has over 20 years of clinical experience. His research program encompasses: rating scale development and measurement-based care in neurological and psychiatric disorders; neuropsychiatric disease epidemiology and diagnosis; nosology, assessment, and management of non-cognitive markers of dementia; neuroimaging and biomarker studies of dementia and predementia syndromes; and dementia clinical trials of interventions for cognitive and non-cognitive outcomes. His research has been funded by Brain Canada, the Canadian Consortium on Neurodegeneration in Aging, and the Canadian Institutes of Health Research.
Dr. Ismail is Chair of the Canadian Consensus Conference on the Diagnosis and Treatment of Dementia, which generates Canadian dementia guidelines, the most recent iteration of which were published in 2020. He is also Chair of the Canadian Conference on Dementia, and past Academic Co-chair of the US Alzheimer’s Association-ISTAART Neuropsychiatric Syndromes Professional Interests Area.
Dr Ismail led the ISTAART development of the neurobehavioural syndrome Mild Behavioural Impairment (MBI) and the MBI Checklist, and co-led development of the new research criteria for biomarker and phenotypic classification of psychosis in AD and related dementias.
Dr. Ismail is a contributor to international working groups advancing nosology in neurodegenerative diseases.
He is an author on the revised IPA criteria for Psychosis in Neurocognitive Disorders, ISCTM-ISTAART criteria for Apathy in Neurocognitive Disorders, and the upcoming revision of the IPA criteria for Agitation in Neurocognitive Disorders.